NCT04306367View on ClinicalTrials.gov

Study of Pembrolizumab and Olaparib in Bile Duct Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

July 16, 2023

Study Completion Date

December 19, 2024

Conditions
Cholangiocarcinoma
Interventions
DRUG

Pembrolizumab

200 mg given intravenously.

DRUG

Olaparib

300 mg given orally.

Trial Locations (1)

20007

Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C.

All Listed Sponsors
lead

Georgetown University

OTHER

NCT04306367 - Study of Pembrolizumab and Olaparib in Bile Duct Cancer | Biotech Hunter | Biotech Hunter